
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
Published on December 31, 2024
expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the
Other news
